RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
October 22, 2018 09:26 ET
|
RedHill Biopharma Ltd.
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy...